Paromomycin containing compounds and method of use
    1.
    发明授权
    Paromomycin containing compounds and method of use 失效
    含有溴霉素的化合物及其使用方法

    公开(公告)号:US4337248A

    公开(公告)日:1982-06-29

    申请号:US156478

    申请日:1980-06-04

    CPC分类号: C07H15/232

    摘要: Compounds are disclosed of the formula ##STR1## wherein R.sub.1 represents a hydrogen or chlorine atom, as well as intermediates. These include 4'-deoxy-paromomycin; 4'-deoxy-4'-epi-chloro-paromomycin; 4'-deoxy-4'-epi-chloro-penta-N-benzyloxycarbonylparomomycin; 4'-deoxy-penta-N-benzyloxycarbonylparomomycin; 6,3',2",5",3"',4"'-hexa-O-acetyl-6'-O-benzoyl-4'-deoxy-penta-N-benzyloxycarbonylparomomycin; 6,3',2",5",3"',4"'-hexa-O-acetyl-6'-O-benzoyl-4'-epi-chloro-4'-deoxy-penta-N-benzyloxycarbonylparomomycin; 6,3',2",5",3"',4"'-hexa-O-acetyl-6'-O-benzyl-penta-N-benzyloxycarbonylparomomycin; 6,3',2",5",3"',4"'-hexa-O-acetyl-6'-O-benzoyl-4'-O-[(methylthio)-thiocarbonyl]-penta-N-benzyloxycarbonylparomomycin; and 6,3',2",5",3"',4"'-hexa-O-acetyl-6'-O-benzoyl-4'-O-[(phenylthio)-thiocarbonyl]-penta-N-benzyloxycarbonylparomomycin. The compounds illustrated by the structural formula are useful in treating amoebic dysentery in man and animals.

    摘要翻译: 公开了下式的化合物:其中R 1表示氢或氯原子,以及中间体。 这些包括4'-脱氧巴马霉素; 4'-脱氧-4'-表 - 氯 - 巴龙霉素; 4'-脱氧-4'-表 - 氯 - 五-N-苄氧羰基巴霉素; 4'-脱氧 - 五-N-苄氧羰基巴霉素; 6,3',2“,5”,3“,4”' - 六-O-乙酰基-6'-O-苯甲酰基-4'-脱氧-5-N-苄氧基羰基巴霉素; 6,3',2“,5”,3“,4” - 六-O-乙酰基-6'-O-苯甲酰基-4'-表氯 - 4'-脱甲基 - 五 -N-苄氧羰基巴霉素; 6,3',2“,5”,3“,4”' - 六-O-乙酰基-6'-O-苄基 - 五-N-苄氧基氨基辛基巴霉素; 6,3',2“,5”,3“,4” - 六-O-乙酰基-6'-O-苯甲酰基-4'-O - [(甲硫基) - 噻吩基] 五-N-苄氧羰基巴霉素; 和6,3',2“,5”,3“,4” - 六-O-乙酰基-6'-O-苯甲酰基-4'-O - [(苯硫基) - 噻吩基] - 五-N-苄氧羰基巴霉素。 由结构式表示的化合物可用于治疗人和动物中的阿米巴痢疾。

    PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES
    2.
    发明申请
    PROCESS FOR THE PREPARATION OF 5-(2-AMINO-PYRIMIDIN-4-YL)-2-ARYL-1H-PYRROLE-3-CARBOXAMIDES 有权
    制备5-(2-氨基 - 嘧啶-4-基)-2-芳基-1H-吡咯-3-羧酸的方法

    公开(公告)号:US20110040090A1

    公开(公告)日:2011-02-17

    申请号:US12989518

    申请日:2009-04-30

    IPC分类号: C07D403/04 C07D207/416

    CPC分类号: C07D403/04

    摘要: The present invention relates to a process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides and to the useful intermediate compounds of such process. 5-(2-Amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides are described and claimed in W02007110344, which also discloses processes for their preparation. These compounds can be advantageously prepared through a process which allows to obtain the desired products in high yields and purity and with a limited number of steps. The synthesis is starting from a cyano pyrrole derivative, and is characterized from the final hydrolysis of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carbonitrile. The compounds prepared according to the process of the present invention are endowed with protein kinase inhibiting activity and, more particularly, Cdc7 or Cdc7/Cdks inhibiting activity. The compounds are therefore useful in the treatment of a variety of cancers, cell proliferative disorders and diseases associated with protein kinases.

    摘要翻译: 本发明涉及制备5-(2-氨基 - 嘧啶-4-基)-2-芳基-1H-吡咯-3-甲酰胺的方法和该方法的有用的中间体化合物。 5-(2-氨基 - 嘧啶-4-基)-2-芳基-1H-吡咯-3-甲酰胺在WO2007110344中进行了描述和要求保护,其也公开了其制备方法。 这些化合物可以有利地通过允许以高产率和纯度以及有限数量的步骤获得所需产物的方法制备。 合成起始于氰基吡咯衍生物,其特征在于5-(2-氨基 - 嘧啶-4-基)-2-芳基-1H-吡咯-3-甲腈的最终水解。 根据本发明的方法制备的化合物具有蛋白激酶抑制活性,更具体地,赋予Cdc7或Cdc7 / Cdks抑制活性。 因此,这些化合物可用于治疗多种癌症,细胞增殖性疾病和与蛋白激酶相关的疾病。

    Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use
    5.
    发明授权
    Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use 失效
    细胞有丝分裂和机制的肽拮抗剂及其治疗用途

    公开(公告)号:US06245742B1

    公开(公告)日:2001-06-12

    申请号:US08930616

    申请日:1997-10-15

    IPC分类号: A61K3800

    摘要: The present invention relates to peptides and peptidomimetic compounds and pharmaceutical compositions containing them as useful pharmacological agents in the control or treatment of proliferative diseases such as cancer, against tumor growing and/or tumoral metastasis, and psoriasis and in the control or treatment of inflammatory, allergic, autoimmune, viral, and cardiovascular diseases. These new compounds have the unique property to inhibit the recognition of several phosphotyrosine containing motifs within all the cellular receptors and cytosolic transducers by a wide spectrum of SH2 domains contained in cytosolic transducers and other effector proteins laying along different pathways of the signal transduction process and with a particularly high affinity for the SH2 domain of the adaptor transducer Grb2, a key element along the pathway to mitogenesis and motogenesis, this last activity leading to invasiveness and to metastasis. The invention also relates to methods for production of the compounds and methods of treatment employing the compounds.

    摘要翻译: 本发明涉及肽和拟肽化合物和药物组合物,其含有它们作为控制或治疗增殖性疾病如癌症,抗肿瘤生长和/或肿瘤转移以及牛皮癣以及控制或治疗炎症, 过敏性,自身免疫性,病毒性和心血管疾病。 这些新化合物具有独特的性质,可以通过广泛的SH2结构域抑制所有细胞受体和细胞溶质转导体中识别的含有多种含磷酸酪氨酸基序,这些SH2结构域包含在信号转导过程不同途径的细胞溶质转导和其他效应蛋白中, 对于适应器传感器Grb2的SH2结构域特别高的亲和力,Grb2是沿着有丝分裂和发育的途径的关键因素,这是导致侵袭和转移的最后一个活动。 本发明还涉及化合物的制备方法和使用该化合物的处理方法。

    Substituted tetralymethylen-Oxindoles analogues as tyrosine kinase
inhibitors
    6.
    发明授权
    Substituted tetralymethylen-Oxindoles analogues as tyrosine kinase inhibitors 失效
    取代的四氢甲基 - 羟吲哚类似物作为酪氨酸激酶抑制剂

    公开(公告)号:US6147073A

    公开(公告)日:2000-11-14

    申请号:US981473

    申请日:1998-01-12

    CPC分类号: C07D209/34

    摘要: A tetralylmethylene-2-oxindole derivative having the following formula (I) ##STR1## wherein one or two of R, R.sub.1, R.sub.2 and R.sub.3 the said two being the same or different, are selected from:a) --X--(CH.sub.2).sub.m --NH.sub.2, --X--(CH.sub.2).sub.m --NR.sub.4 R.sub.5 or --X--(CH.sub.2).sub.m --NHR.sub.6, in which X is --O--, --S-- or --NH--, m is an integer of 2 to 4, one of R.sub.4 and R.sub.5 is hydrogen or C.sub.1 -C.sub.6 alkyl and the other is C.sub.1 -C.sub.6 alkyl or R.sub.4 and R.sub.5 taken together with the N atom to which they are linked form a 5 to 7 membered saturated heteromonocycle, and R.sub.6 is C.sub.2 -C.sub.6 alkanoyl or a C-terminally linked peptidyl residue containing from 1 to 3 aminoacids wherein the terminal amino group is either free or protected or in an alkylated form to provide a --NR.sub.4 R.sub.5 group in which R.sub.4 and R.sub.5 are as defined above.

    摘要翻译: PCT No.PCT / EP97 / 02672 Sec。 371日期:1998年1月12日 102(e)日期1998年1月12日PCT提交1997年5月15日PCT公布。 公开号WO97 / 45409 日期1997年12月4日具有下式(I)的四亚甲基-2-羟基吲哚衍生物,其中所述两个相同或不同的R 1,R 2,R 2和R 3中的一个或两个选自:a)-X-( CH2)m-NH2,-X-(CH2)m-NR4R5或-X-(CH2)m-NHR6,其中X是-O - , - S-或-NH-,m是2〜4的整数 R 4和R 5中的一个是氢或C 1 -C 6烷基,另一个是C 1 -C 6烷基或R 4和R 5与它们所连接的N原子一起形成5至7元饱和杂单环,并且R 6是C 2 - C6链烷酰基或含有1至3个氨基酸的C末端连接的肽基残基,其中末端氨基是游离的或被保护的或以烷基化形式提供,其中R4和R5如上所定义的-NR4R5基团。

    Substituted quinolymethylen-oxindole analogues as tyrosine kinase
inhibitors
    7.
    发明授权
    Substituted quinolymethylen-oxindole analogues as tyrosine kinase inhibitors 失效
    取代的喹喔啉甲氧基吲哚类似物作为酪氨酸激酶抑制剂

    公开(公告)号:US5905149A

    公开(公告)日:1999-05-18

    申请号:US983516

    申请日:1998-01-29

    摘要: Quinolylmethylen-oxindole derivatives having general formula (I), wherein R is H or --(CH.sub.2).sub.n --COR.sub.7 group in which n is an integer of 1 to 4 and R.sub.7 is hydroxy, amino, C.sub.1 -C.sub.6 alkoxy or --NR.sub.5 R.sub.6 in which one of R.sub.5 and R.sub.6 is hydrogen or C.sub.1 -C.sub.6 alkyl and the other is C.sub.1 -C.sub.6 alkyl or R.sub.5 and R.sub.6 taken together with the N atom to which they are linked form a 5 to 7 membered saturated heteromonocycle or R.sub.7 is a N-terminally linked peptidyl residue containing from 1 to 3 aminoacids in which the terminal carboxyl group may be present as such, as amide, as alkali metal salt or as a C.sub.1 -C.sub.4 alkyl ester, one or two of R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, are selected from: a) --X--(CH.sub.2).sub.m --NH.sub.2, --X--(CH.sub.2).sub.m --NR.sub.5 R.sub.6 or --X--(CH.sub.2).sub.m --NHR.sub.8 group; b) --NH--C(.dbd.NH)--NR.sub.5 R.sub.6, --NH--C(.dbd.NH)--NHR.sub.8, --N.dbd.CH--NH.sub.2, --N.dbd.CH--NR.sub.5 R.sub.6 or --N.dbd.CH--NHR.sub.8 group; c) --X--(C.sub.2).sub.n --COR.sub.7 group; d) --COR.sub.a or --COR.sub.9 group; e) --Y--CO--Y'--R.sub.10 group; and f) --NHR.sub.8 or --NHR.sub.11 group and the pharmaceutically acceptable salts thereof, are tyrosine kinase inhibitors.

    摘要翻译: PCT No.PCT / EP97 / 02673。 371日期1998年1月29日 102(e)日期1998年1月29日PCT提交1997年5月15日PCT公布。 公开号WO97 / 46551 日本1997年12月11日具有通式(I)的喔苯基亚甲基 - 羟基吲哚衍生物,其中R为H或 - (CH 2)n -COR 7基,其中n为1〜4的整数,R 7为羟基,氨基,C 1 -C 6烷氧基 或-NR 5 R 6,其中R 5和R 6中的一个为氢或C 1 -C 6烷基,另一个为C 1 -C 6烷基或R 5和R 6与它们所连接的N原子一起形成5至7元饱和杂单环或R7 是含有1至3个氨基酸的N-末端连接的肽基残基,其中末端羧基可以原样存在,作为酰胺,作为碱金属盐或作为C 1 -C 4烷基酯,R 1,R 2, R 3和R 4可以相同或不同,选自:a)-X-(CH 2)m -NH 2,-X-(CH 2)m -NR 5 R 6或-X-(CH 2)m -NHR 8基团; b)-NH-C(= NH)-NR 5 R 6,-NH-C(= NH)-NHR 8,-N = CH-NH 2,-N = CH-NR 5 R 6或-N = CH-NHR 8基团; c)-X-(C2)n-COR7基团; d)-COR a或-COR 9基团; e)-Y-CO-Y'-R10基团; 和f)-NHR 8或-NHR 11基团及其药学上可接受的盐是酪氨酸激酶抑制剂。

    Terpenoidic derivatives useful as antitumor agents
    10.
    发明授权
    Terpenoidic derivatives useful as antitumor agents 失效
    用作抗肿瘤剂的萜类衍生物

    公开(公告)号:US5869514A

    公开(公告)日:1999-02-09

    申请号:US765436

    申请日:1997-01-15

    CPC分类号: A61K31/4178

    摘要: A method of treating tumors in a human or animal by administering thereto a pharmaceutically effective amount of a Sarcodictyin compound selected from Sarcodictyin A, B, C, D, E, and F. Sarcodictyin A has the formula (-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy3,4,4a,7,10,11,12,12a-octahydro-7-hydroxy-6-(methoxy-carbonyl)-1,10- dimethyl-4-(1-methylethyl)benzo cyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl) acrylate (Sarcodictyin A).

    摘要翻译: PCT No.PCT / EP96 / 01688 Sec。 371日期1997年1月15日 102(e)日期1997年1月15日PCT 1996年4月23日PCT PCT。 出版物WO96 / 36335 日本1996年11月21日一种通过向其施用药学有效量的选自Sarcodictyin A,B,C,D,E和F的Sarcodictyin化合物来治疗人或动物肿瘤的方法。Sarcodictyin A具有式( - ) - (4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-环氧基3,4,4a,7,10,11,12,12a-八氢-7-羟基-6-( 甲氧基羰基)-1,10-二甲基-4-(1-甲基乙基)苯并环十一碳烯-11-基(E)-3-(1-甲基-1H-咪唑-4-基)丙烯酸酯(Sarcodictyin A)。